The research company Dextech reports data showing stable disease for patients who have been treated with Osteodex (ODX) in the myeloma study.The last patient in dose group 2 (6 mg/kg) was treated in week 50 and at that time continued to have stable disease. At the same time, all patients in dose group 3 (9 mg/kg) have achieved stable disease and are finished with treatment by the end of February. No significant side effects have been observed."Data obtained so far show that the disease-slowing effect in some cases persists for months and at most up to six months without initiation of any other cancer treatment", the company writes in a press release.Vd Anders Holmberg comments: "We are very satisfied with the study results obtained so far, which are far better than we dared hope for. These strengthen the view of ODX as a candidate for the treatment of treatment-resistant multiple myeloma, and moreover without significant side effects".